



# Adjuvant Transgingival Therapy with Visible Light Plus Water-Filtered Infrared-A (VIS + wIRA) in Periodontal Therapy—A Randomized, Controlled, Stratified, Double-Blinded Clinical Trial

Stefanie Anna Peikert <sup>1,\*</sup>, Anil Fischer <sup>1,2</sup>, Anne Brigitte Kruse <sup>1</sup>, Ali Al-Ahmad <sup>1</sup>, Johan Peter Woelber <sup>1</sup>, Kirstin Vach <sup>3</sup>, Andreas Braun <sup>4</sup> and Petra Ratka-Krüger <sup>1</sup>

- <sup>1</sup> Department of Operative Dentistry and Periodontology, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106 Freiburg, Germany; anil.fischer@googlemail.com (A.F.); anne.kruse@uniklinik-freiburg.de (A.B.K.); ali.al-ahmad@uniklinik-freiburg.de (A.A.-A.); johan.woelber@uniklinik-freiburg.de (J.P.W.); petra.ratka-krueger@uniklinik-freiburg.de (P.R.-K.)
- <sup>2</sup> Practice Dr. Stefan Bertram, Gewerbegasse 5, 83395 Freilassing, Germany
- <sup>3</sup> Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Stefan-Meier-Straße 26, 79104 Freiburg, Germany; kv@imbi.uni-freiburg.de
- <sup>4</sup> Clinic for Operative Dentistry, Periodontology and Preventive Dentistry, RWTH University Aachen, Pauwelsstraße 30, 52074 Aachen, Germany; anbraun@ukaachen.de
- \* Correspondence: stefanie.peikert@uniklinik-freiburg.de; Tel.: +49-761-270-48800

**Abstract:** The aim of this randomized, controlled, double-blinded clinical trial was to examine the additional healing effect of transgingival visible light and water-filtered infrared-A (VIS + wIRA) in the treatment of periodontitis patients compared with the standard therapy by subgingival instrumentation (SI). Therefore, forty patients with untreated periodontitis received a non-surgical periodontal treatment. Using a split-mouth study design, one quadrant of the upper jaw was randomly either exposed to VIS + wIRA four times for 20 min within two weeks in addition to SI or received only SI. Three and 6 months after intervention, clinical parameters (probing depths (PDs), clinical attachment level, bleeding on probing (BOP), furcation, tooth mobility, plaque control record, and papilla bleeding index) were re-evaluated. In the presence of PD of 4 mm and positive BOP or PD > 4 mm, SI was performed again. Moreover, the patients were asked about their discomfort using a visual analog scale from 1 to 10 for each side of the maxilla. Statistical analysis demonstrated no differences between quadrants at re-evaluation for clinical parameters (p > 0.05) after 3 and 6 months. Concerning pain perception, patients described less pain on the irradiated side (p = 0.016). In the treatment of patients with periodontitis, VIS + wIRA did not show an additional effect on the clinical outcome after 3 and 6 months. Patients described less pain on the irradiated quadrant after treatment.

Keywords: antibiotic resistance; antimicrobial therapy; periodontitis; adjuvant periodontal therapy

# 1. Introduction

According to the Global Burden of Disease Study, the severe form of periodontitis was the sixth-most prevalent condition in the world [1]. The main etiological factor for the genesis of periodontal inflammation is a host-mediated dysbiotic bacterial biofilm. The current basic therapy of periodontitis consists mainly of the disintegration of the subgingival biofilm. This is usually achieved by removing concrements, bacteria, and toxins from the tooth surface by subgingival instrumentation (e.g., with curettes or ultrasonic instruments) [2]. Sometimes, the use of antibiotics in addition to mechanical cleaning is also indicated [3]. However, because of the increasing number of antibiotic-resistant microorganisms in the treatment of periodontitis, alternative therapy options are increasingly needed [4,5]. In other medical fields, the combination of a wide band light source with visible light wavelengths (VIS) and water-filtered infrared A (wIRA) wavelengths showed



Citation: Peikert, S.A.; Fischer, A.; Kruse, A.B.; Al-Ahmad, A.; Woelber, J.P.; Vach, K.; Braun, A.; Ratka-Krüger, P. Adjuvant Transgingival Therapy with Visible Light Plus Water-Filtered Infrared-A (VIS + wIRA) in Periodontal Therapy—A Randomized, Controlled, Stratified, Double-Blinded Clinical Trial. *Antibiotics* **2021**, *10*, 251. https://doi.org/10.3390/antibiotics 10030251

Academic Editor: Carlos M. Franco

Received: 1 February 2021 Accepted: 26 February 2021 Published: 3 March 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). promising effects to treat various medical disorders owing to its thermal effect [6,7]. The healing effect of hyperthermia was already known to the ancient Greeks [8]. Fever is the body's response to various stimuli of the immune system. Thus, it is also not surprising that body temperature has a strong influence on the modulation of the immune system. For example, dendritic cells stimulate and activate increased T cells at fever-like temperatures [9]. Macrophage behavior is also temperature-dependent. Thus, they showed a 40% higher phagocytosis capacity at temperatures of 40 °C than at 37 °C [10]. Besides, thermal stress leads to upregulation of toll-like receptor 4 (TLR4) expression in antigen-presenting cells (APC) and increased cytokine and NO release [11]. Increased expression of TLR4, in turn, promotes a T helper cell 1 (Th1) immune response, which has been associated with increased resistance to periodontitis [12–14].

Furthermore, fever-like temperatures also appear to affect microorganisms. Specifically, Gram-negative pathogens undergo enhanced lysis by blood serum after incubation at fever-like conditions [15]. *Porphyromonas gingivalis* showed an altered folding and synthesis of lipid A molecules in vitro with increasing temperature up to 41 °C, resulting in significantly enhanced activation of TLR-4 [16]. Moreover, *P. gingivalis* produced fewer virulence factors when the temperature was increased from 37 °C to 39 °C [17]. Further, fibroblasts and endothelial cells exposed to mild temperature stress (1 h at 41 °C) showed slowed cell ageing and an accelerated angiogenesis rate [18]. Direct application of heat also positively affects bone regeneration and mineralization [19,20].

VIS + wIRA is a promising possibility with a high transgingival subcutaneous tissue penetration (2–3 cm), which allows for the exposure of the periodontal pockets [7,21,22]. Besides, VIS in combination with wIRA has a low thermal surface load, allowing for the transport of high energy into tissues [23]. Furthermore, VIS + wIRA leads to an increase of the tissue temperature in the deep, oxygen partial pressure in the treated tissue and tissue perfusion, which also transports the warmth to the surrounding tissues, showing improved healing of chronic wounds after application and association with pain reduction [22,24].

All these described effects and characteristics would make VIS + wIRA interesting for adjuvant use in periodontal therapy. Therefore, this study aimed to develop a possible application form for the use of VIS + wIRA in the oral cavity, whereby a transgingival therapy of several periodontal sites can be achieved simultaneously, as well as to investigate the tissue healing effect of VIS + wIRA in the treatment of periodontal disease in the first step.

#### 2. Results

A total of 46 patients were pre-examined for the study, of which 40 patients were treated with the described protocol. Six patients had to be excluded because of not appearing after successful pre-treatment/information, incorrect diagnosis in the recruitment phase, and extraction therapy by non-participating dentists. Out of 40 patients treated with VIS + wIRA, a total of 39 could be re-examined after 3 months. One patient had to be excluded owing to "repeated absence at the follow-up appointment". After 6 months, 31 patients could be re-examined. Seven did not appear for the follow-up appointment. One patient received a subgingival instrumentation outside the study protocol in the meantime and one patient's data had to be excluded because of a storage error (Figure 1).

No adverse events were recorded during the study period.

At baseline, 22 men (55%) and 18 women (45%) were examined, with an average age of 54.43 years. Eleven (27.5%) participants were classified as smokers. Demographic data at baseline are presented in Table 1.

Excluded (n = 6)• Not meeting inclusion criteria (*n* = 1) • Declined to participate (*n* = 4) • Other reasons (*n* = 1) Randomized (n = 40)Allocation Allocated to intervention curettes (n = 40)Received allocated intervention (n = 40)Did not receive allocated intervention (n = 0)

Follow-Up

Lost to follow up (n = 9)

3 months (n = 1)1× did not show up

Analysed (n = 31)

6 months (n = 8)6× did not show up 1× subgingival instrumentation outside the study protocol 1× storage error

Figure 1. Consort diagram. VIS, visible light; wIRA, water-filtered infrared A; n stands for the number of study participants.

Parameter

**Table 1.** Demographic data at baseline (absolute numbers, mean  $(\pm sd)$ , or percentages). VIS, visible light; wIRA, water-filtered infrared A.

40 (18 female, 22 male)
n = 40 (VIS + wIRA); $n = 40$ (control)
54.43 (± 10.57)
72.75% non-smokers, 27.5% smokers

At baseline, there were no significant differences between the control and the VIS + wIRA treated sextants for pocket depths (PD), bleeding on probing (BOP), clinical attachment level (CAL), plaque control record (PCR), and papilla bleeding index (PBI) (Table 2).

additional VIS+wIRA (n = 40)

Did not receive allocated intervention (n = 0)

Assessed for eligibility (n = 46)

Lost to follow-up (n = 9)

3 months (n = 1)1× did not show up

6 months (n = 8)6× did not show up 1× subgingival instrumentation outside the study protocol 1× storage error

**Analysis** 

Analysed (n = 31)

Allocated to intervention curettes and

Received allocated intervention (n = 40)

Enrollment

**Table 2.** Mean values ( $\pm$ SD) for plaque control record (PCR), papilla bleeding index (PBI), probing depth (PD), bleeding on probing (BOP), clinical attachment level (CAL), furcation, and tooth mobility (teeth 4 to 8 with PD  $\geq$  4 mm to  $\leq$ 7 mm) at baseline, 3 months, and 6 months for the test group (VIS + wIRA) and the control group (hand instrumentation with Gracey curettes).

Variable		Group	Baseline = BL ( <i>n</i> Control = 113, <i>n</i> Test = 112)	Difference Value BL vs. 3 Months ( <i>n</i> = 39)	<i>p-</i> Value	Difference Value BL vs. 6 Months (n = 31)	<i>p</i> -Value
PCR %		Control Test	21.46 (23.59) 22.76 (23.38)	2.92 (0.22) -0.59 (0.20)	p = 0.375	2.80 (0.21) 4.97 (0.26)	<i>p</i> = 0.833
PBI %		Control Test	39.82 (75.04) 42.85 (86.69)	-5.08 (0.77) -11.15 (0.79)	<i>p</i> = 0.173	-17.74 (0.71) -23.27 (0.82)	<i>p</i> = 0.265
PD <sup>1</sup> (mm)		Control Test	4.58 (0.65) 4.58 (0.67)	-0.83 (0.62) -0.88 (0.53)	<i>p</i> = 0.453	$-0.93 (0.53) \\ -1.03 (0.55)$	<i>p</i> = 0.278
PD <sup>2</sup> (mm)		Control Test	4.55 (0.68) 4.54 (0.67)	-0,86 (0.61) -0,99 (0.53)	<i>p</i> = 0.047 *	-1.10 (0.86) -1.22 (0.86)	<i>p</i> = 0.065
BOP %		Control Test	55.01 (28.68) 51.63 (28.64)	-16.64 (0.29) -18.61 (0.22)	p = 0.639	-22.90 (0.30) -25.12 (0.23)	p = 0.991
CAL (mm)		Control Test	5.23 (1.40) 5.22 (1.33)	-0.86 (0.77) -0.91 (0.68)	p = 0.708	-0.92 (0.69) -0.95 (0.68)	p = 0.794
Furcation	mesial <sup>#</sup>	Control Test	0.23 (0.60) 0.32 (0.75)	-0.01 (0.33) 0.03 (0.22)	p = 0.540	0.02 (0.33) -0.02 (0.50)	<i>p</i> = 0.992
	distal <sup>#</sup>	Control Test	0.59 (0.91) 0.47 (0.79)	-0.14 (0.60) -0.11 (0.63)	p = 0.576	-0.16 (0.66) -0.13 (0.68)	p = 0.716
	vestibular <sup>#</sup>	Control Test	0.56 (0.86) 0.54 (0.78)	-0.09 (0.56) -0.06 (0.52)	p = 0.920	-0.13 (0.59) -0.17 (0.56)	<i>p</i> = 0.113
Mobility #		Control Test	0.25 (0.58) 0.13 (0.43)	-0.05 (0.38) -0.02 (0.38)	<i>p</i> = 0.519	$-0.08 (0.46) \\ -0.05 (0.40)$	<i>p</i> = 0.638

\* statistically significant. BL = baseline. <sup>1</sup> Calculated values for teeth 4–8; <sup>2</sup> calculated values for teeth 1–8. Data are presented as means and standard deviation, which is given in parentheses. In the baseline examination, *n* stands for the number of teeth; otherwise, *n* stands for the number of study participants. <sup>#</sup> The median is 0 in both groups at BL.

# 2.1. Plaque Control Record (PCR)

The average PCR related to the full dentition deteriorated with a longer period between pre-treatment from 17.47% at baseline to 19.80% after 3 months and 22.01% after 6 months. Referring to teeth 4 to 8 with PD  $\geq$  4 mm to  $\leq$ 7 mm, a difference of -0.59%compared with baseline was seen on the VIS + wIRA exposed side after 3 months. After 6 months, a difference of 4.97% versus baseline was observed. Overall, in the inter-group comparison, no significant difference was found between the two treatment methods (after 3 months, *p* = 0.375; after 6 months *p* = 0.833).

#### 2.2. Papilla Bleeding Index (PBI)

The average PBI related to the full dentition improved with a longer time interval to pre-treatment from 41.70% at baseline to 26.41% after 3 months and 19.14% after 6 months. Furthermore, the sextant treated with VIS + wIRA (teeth 4–8 with PD  $\geq$ 4 mm and  $\leq$ 7 mm in the upper jaw) showed a tendency toward increased reduction of PBI at the third (p = 0.173) and sixth (p = 0.265) monthly findings in the inter-group comparison, but without being statistically significant.

# 2.3. Probing Depths (PDs)

In the inter-group comparison, no significant reduction of the PDs in the VIS + wIRA treated sextant (teeth 4–8 in the maxilla with PDs between  $\geq$ 4 mm and  $\leq$ 7 mm) could be found after 3 (p = 0.453) and 6 months (p = 0.278) compared with the untreated side.

As the level of PD reduction also depends on the initial PD, teeth 4–8 with low PDs between  $\geq$ 4 mm and  $\leq$ 5 mm and teeth 4–8 with moderate PDs between  $\geq$ 6 mm and  $\leq$ 7 mm were evaluated separately. However, no significant difference between the two treatment methods could be observed.

Only by evaluating the PD reduction for teeth 1–8 (ST  $\geq$  4 mm and  $\leq$  7 mm) was a significantly higher reduction determined in the quadrant treated with VIS + wIRA for the third month finding (*p* = 0.047). However, no significance was found at the sixth month finding.

# 2.4. Bleeding on Probing (BOP)

Concerning BOP, there was no significant difference between the VIS + wIRA treated sites and the unexposed sites after 3 (p = 0.639) and 6 months (p = 0.991) in the intergroup comparison.

#### 2.5. Clinical Attachment Level (CAL)

The results for the third and sixth months showed a tendency toward a higher level of attachment gain in the VIS + wIRA treated sextants compared with the control (0.041 mm; 0.023 mm); however, the difference of this inter-group comparison is not significant (p = 0.708; p = 0.794).

#### 2.6. Furcation

The changes in furcation were compared for treated teeth 4, 6, 7, and 8 (ST  $\geq$  4 mm and  $\leq$  7 mm) in the maxilla. The sites were considered separately (mesial, distal, and vestibular). Neither the third nor the sixth month findings showed a significant difference between the two treatment methods.

#### 2.7. Tooth Mobility

No statistically significant difference between VIS + wIRA sites and the control sites could be found at the time of follow-up examinations after 3 (p = 0.519) and 6 months (p = 0.638).

All results for PCR, PBI, PD, BOP, CAL, furcation, and tooth mobility are summarized in Table 2 (third and sixth month findings). In order to compare the two methods after both 3 and after 6 months, linear mixed models adjusted for sex and age were used. However, both factors had no influence.

#### 2.8. Temperature Measurement

The temperature measurement was carried out on a total of 37 test participants. Three patients had to be excluded because of technical problems with the temperature probe. The mean measured sublingual temperature was 36.13 °C. Furthermore, the temperatures in the control sextants and in the sextants treated with VIS + wIRA were measured before and after 20 min of VIS + wIRA treatment (Table 3). Temperature in the exposed sextant increased significantly (3.73 °C) compared with the control sextant (0.68 °C). Additional infrared sample images were taken before and after the VIS + wIRA treatment (Figure 2). Here, it became clear that the VIS + wIRA treatment mainly affects the treated sextant, but the remaining facial area including adjacent structures is also warmed up.

			п	Mean	Std. Dev.
Sublingual temperature			37	36.13 °C	0.43 °C
Temperature	0 min	Control VIS + wIRA	37 37	35.38 °C 35.27 °C	0.73 °C 0.74 °C
region	20 min	Control VIS + wIRA	37 37	36.06 °C 39.00 °C	0.58 °C 0.55 °C

Table 3. Temperature measurement before and 20 min after VIS + wIRA treatment.

n = number of study participants, Mean = mean value, Std. Dev. = standard deviation.



**Figure 2.** Images taken by thermographic camera before and after VIS + wIRA treatment: (**a**) infrared image taken before VIS + wIRA treatment; (**b**) infrared image taken after 20 min of VIS + wIRA treatment.

# 3. Discussion

The aim of this randomized, controlled, double-blinded clinical trial was to examine the additional healing effect of transgingival visible light and water-filtered infrared-A (VIS + wIRA) in the treatment of periodontitis patients compared with the standard therapy by subgingival instrumentation. The collected data did not show significant differences between subgingival instrumentation followed by the exposure by VIS + wIRA and subgingival instrumentation alone for the clinical outcome at 3 and 6 months after treatment. However, assessing the pain perception by visual analog scale (VAS) patients reported reduced pain on the irradiated quadrant.

The adjuvant therapy of periodontitis with VIS + wIRA has not yet been described in the literature; therefore, the results are not comparable to those of other studies, although evidence for the treatment with VIS + wIRA could be obtained from other medical fields, such as surgery or dermatology [25–27]. It is already known thanks to other studies that VIS + wiRA enhances the surrounding tissues and promotes their biological function. Studies have shown that fibroblasts and endothelial cells exposed to mild temperature stress (1 h at 41 °C) demonstrated slowed cell aging and an accelerated angiogenesis rate (Rattan et al., 2007). Furthermore, direct application of heat positively affects bone regeneration and mineralization and increases osteogenetic differentiation [19,20,28].

Another research group investigated the effect of increasing temperature up to 41  $^{\circ}$ C on the behavior of rat dental follicular stem cells. It was shown that, with increasing temperature up to 40  $^{\circ}$ C, these not only showed a higher cell division rate, but also increased osteogenetic differentiation, which was additionally accompanied by increased bone mineralization from 39  $^{\circ}$ C onwards. This suggests that VIS + wiRA may also have a positive effect on periodontal tissues.

However, in contrast to this study, most patients in the studies already conducted in the medical field were treated as inpatients 1–2 times a day for several weeks for 20–30 min

with VIS + wIRA [7,25,27,29]. Within the scope of these above-mentioned studies, the wound healing promoting effect as well as the prevention or decrease of wound infections could be demonstrated. In contrast, our study showed a pain reducing effect of VIS + wIRA, but no apparent impact on the healing process of the periodontal inflammation.

In addition, tissue temperature increased following exposure with VIS + wIRA after 20 min to 39.01 °C, indicating that a sufficient amount of energy was transferred to the surrounding tissue in order to show possible wound healing stimulating effects. This corresponds to previous studies describing beneficial wound healing effects for a temperature range between 37 and 39 °C [22,29]. In contrast, only a slight temperature increase (+0.68 °C) was observed in the unexposed areas, which did not exceed the sublingual temperature (36.14 °C). Compared with tooth irradiation with a halogen lamp, which causes a temperature increase of 5 °C after 45–60 s [30], no adverse heating effects were shown for the irradiation using VIS + wIRA for longer time periods of up to 30 min [21]. Lastly, in a forthcoming study, the temperature measurement would have to be carried out directly in the periodontal pocket in order to make an even more accurate assessment of the temperature increase caused by VIS + wIRA.

The reduction of probing depths after 3 months (0.84 mm (control); 0.89 mm (VIS + wIRA)) and 6 months (0.93 mm (control); 1.03 mm (VIS + wIRA)) correlate with the results of other studies on non-surgical periodontitis therapy [31-34]. The strongest reduction in probing depths can be expected 1–3 months after intervention; however, further healing processes were proven up to 9–12 months after treatment [35-38]. For this reason, patients in this study were re-evaluated after 3 and 6 months, also observing a further reduction of probing depths between the third and sixth month findings. Regarding the BOP, this study showed a reduction of 30.25% and 41.63% for the third and sixth month findings, respectively, for the control and 36.05% and 48.65%, respectively, for the teeth treated with VIS + wIRA. These results are consistent with those reported in the literature [39].

Similar results could also be achieved regarding the clinical attachment gain. According to Cobb et al., the average attachment gain after non-surgical periodontal therapy is about 0.55 mm for pockets from 4 to 6 mm probing depth and 1.19 mm for pockets greater than 7 mm probing depth [39]. With an attachment gain of 0.87 mm (control) and 0.91 mm (VIS + wIRA) after 3 months and 0.93 mm (control) and 0.95 mm (VIS + wIRA), respectively, at the sixth month finding with an average pocket depth of 4.58 mm at the beginning of the examinations, an excellent result could be achieved in both the VIS + wIRA group and the control group.

Furthermore, no significant difference in the degree of furcation could be observed after either 3 or 6 months between the two treatment methods. According to Reddy et al., a stagnation of furcation can only be achieved with a low degree of furcation by non-surgical periodontal therapy. However, without surgical regenerative therapy, no healing can be expected [40].

Patient comfort was higher after subgingival instrumentation when VIS + wIRA was applied adjunctively. Of course, it should be noted that the classification of pain intensity is subjective owing to the lack of a placebo group [41]. However, the results of this study correlate with previous studies on the effect of VIS + wIRA on abdominal wound healing following elective gastrointestinal surgery [22]. In a prospective, randomized, controlled, double-blind study with 94 patients after major abdominal surgery, Hartel et al., 2007 described a significant pain reduction of 13.4 mm on a visual analog scale (VAS) of 100 mm in the VIS + wIRA group (n = 46) compared with control (n = 48), where pain remained unchanged after 230 single irradiations. In addition, the need for painkillers could be reduced by 57–70%. The reason for this could be the improved tissue perfusion, which increases the removal of metabolites such as pain mediators, lactate, and bacterial toxins, as well as the improved tissue oxygen partial pressure in the area treated with VIS + wIRA [22].

The aim of this study was to investigate the clinical outcomes of applying VIS + wIRA in addition to standard therapy by subgingival instrumentation. The healing process

depends on the oral subgingival biofilm, which could be influenced by this novel treatment method. This could save the use of additional antibiotics and avoid the development of antimicrobial resistance. However, no microbiological and immunological analyses were performed in this study. Future studies could further investigate the effect of the application of VIS + wIRA of the subgingival biofilm and immunological processes. Although the main etiological factor for the genesis of periodontal inflammation is a host-mediated dysbiotic bacterial biofilm, the severity of inflammation is also manifested in clinical parameters. Moreover, clinical parameters also indirectly provide information about immunologic status. In this study, no significant differences in the clinical parameters were found between standard therapy and additional treatment with VIS + wIRA, so further microbial analysis is questionable.

Furthermore, VIS + wIRA could also be used to activate a photosensitizer in the context of antimicrobial photodynamic therapy (aPDT). Promising data are already available from in vitro studies on supra- and subgingival oral biofilm with photosensitizers activated by VIS + wIRA [21,42]. Nevertheless, the frequency of use investigated in this study was sufficient for the transgingival antimicrobial photodynamic therapy with a photosensitizer [43–45]. Only if the energy reaching the sulcus is high enough could VIS + wIRA be used for transgingival activation of a photosensitizer, which would significantly simplify the procedure of aPDT. However, this needs to be clarified in future studies.

No adverse events were recorded throughout the study.

Although there was no placebo group, the split-mouth design provided a way to generate coherent clinical data for two different treatment regimens. However, a few limitations have been observed in the study. The follow-up was conducted over a limited period of 6 months. Therefore, no statement can be made about long-term effects on the clinical outcome for the control and VIS + wIRA group.

#### 4. Materials and Methods

The study was conducted as a split-mouth designed, randomized, controlled, stratified, double-blinded clinical trial with patients undergoing a non-surgical periodontal therapy (NST).

#### 4.1. Inclusion Criteria

- Age  $\geq$  18 years;
- Untreated periodontal disease (at least two teeth with a probing depth (PD) ≥4 mm and ≤8 mm in diverse quadrants (the following combinations were possible: I/II, I/III, II/IV);
- No systematic periodontal treatment in the last 12 months;
- No antibiotic intake in the last 6 months [46];
- Maximum 30% smokers [47].

# 4.2. Exclusion Criteria

- Surgical periodontal therapy;
- Antibiotic intake during the study period;
- Pregnancy;
- Serious systemic conditions (for example, HIV, immunosuppression);
- Patients who needed antibiotic prophylaxis prior to the periodontal examination;
- Special anatomical tooth position such as infraposition, strong inclination, gingival overgrowth.

#### 4.3. Care-Giver and Patient Recruitment

Patients who participated in the study were recruited from November 2016 until July 2017 in the Department of Operative Dentistry and Periodontology of the University of Freiburg in Germany.

The patients were initially checked using the Community Periodontal Index of Treatment Needs (CPITN) [48]. From the value 3 or 4 in one or more sextants, the indication of periodontal treatment was given. After checking the inclusion and exclusion criteria, patients were informed about the study and asked about participation. Patients received €100 as reimbursement for participating in the study.

# 4.4. Clinical Measurements and Procedures

Before starting the study, the investigator was subjected to a calibration process. For this purpose, the investigator measured probing depths (PDs), plaque control record (PCR) [49], and papilla bleeding index (PBI) [50] on various volunteers until they corresponded to at least 75% with the results of a long-term periodontal specialist [51].

As part of the systematic therapy, each patient received periodontal pre-treatment (professional tooth cleaning in combination with personalized oral self-care instructions). Afterwards, a baseline assessment was performed by the calibrated and blinded investigator (PD in mm at six sites per tooth, clinical attachment level (CAL) in mm at six sites per tooth, bleeding on probing (BOP) in %, at six sites per tooth, furcation, tooth mobility, PCR, and PBI). In one quadrant, PDs were measured twice to calculate the intra-rater variance. Subsequently, all PDs > 4 mm were treated by hand instrumentation with curettes (Gracey curettes, Hu Friedy, Chicago, IL, USA).

The allocation of the quadrant to be treated with VIS + wIRA was randomized by the responsible statistician (STATA 14 software; StataCorp LLC, College Station, TX, USA). Sealed envelopes for the quadrant treated with VIS + wIRA for each participant were prepared according to the randomization list and were only opened after the periodontal pre-treatment and the baseline assessment to identify which quadrant is supportively treated with VIS + wIRA.

A modified VIS + wIRA radiator (Hydrosun 750 FS, Hydrosun Medizintechnik GmbH, Müllheim, Germany) with a 7 mm water cuvette was used as a radiation source. According to the manufacturer, the infrared source (USHIO, Cypress, CA, USA) delivers 15,600 lumens at a color temperature of 3050 K. The cuvette serves as a light filter and absorbs especially in the infrared B and C range. In addition, the light is filtered through a dichroic color filter BTE 595 orange (Bte Bedampfungstechnik GmbH, Elsoff, Germany), which is only transparent to wavelengths  $\geq$ 595 nm. Consequently, VIS + wIRA is a special electromagnetic wave spectrum in the range of 780–1400 nm. In order to apply the light with sufficient intensity in a quadrant, it was transmitted via a light guide to individually manufactured splints (Makerbot Replicator, MakerBot Industries, Brooklyn, NY, USA). According to the manufacturer, the total power density at the end pieces is 450 mW/cm<sup>2</sup>. After subgingival instrumentation of all diseased teeth with Gracey curettes, only one quadrant was additionally treated with VIS + wIRA for 20 min. Within the following 2 weeks, the treatment with VIS + wIRA was repeated four times for 20 min at a time (Figure 3).



Figure 3. Exposure of a participant with VIS + wIRA.

After 3 and 6 months, the follow-up examinations were carried out. In the presence of PD of 4 mm and positive BOP or PD > 4 mm, SI was performed again.

# 4.5. Temperature Measurement

Using a temperature probe with a diameter of 0.25 mm (Testo AG, Lenzkirch, Germany, Type K t/c No. 0602.0493) and a thermometer (Testo AG, Lenzkirch, Thermometer Testo 735), the sublingual temperature and the temperature at a previously determined location in the direct radiation area in the first and third sextant of the maxilla was measured before the treatment with VIS + wIRA. After 20 min of radiation, the measurement was repeated and determined in the first and third sextant of the maxilla.

#### 4.6. Pain Perception

Immediately after treatment, the patients were interviewed about their discomfort according to a visual analog scale from 1 to 10 (VAS) for each side of the maxilla [52].

#### 4.7. Sample Size and Statistical Considerations

Sample size calculation and analysis of the results was conducted by a statistician (KV). It was calculated that, with a sample size of 34 patients, a difference in PD of 0.5 mm with a standard deviation of 1 can be shown with a power of 80% in a split-mouth design. Owing to dropouts, a sample size of 40 was planned.

For descriptive analysis, mean and standard deviations were computed. A paired t-test was used to compare the different parameters at baseline.

Linear mixed models were fitted to compare the two methods at both 3 and 6 months, and sex and age were used for adjustment. Pain density was compared using the Wilcoxon matched-pairs sign-test.

# 5. Conclusions

The adjuvant treatment with VIS + wIRA as part of the systematic periodontal therapy did not show an additional effect on the clinical outcomes after 3 and 6 months. However, it was possible to develop an application form for the use of VIS + wIRA in the oral cavity, whereby a transgingival thermal therapy for the periodontium of several teeth was achieved simultaneously. Consequently, future studies for the transgingival photodynamic therapy with VIS + wIRA in combination with a photosensitizer can be conducted. Furthermore, patients reported less pain on the irradiated side after treatment.

**Author Contributions:** Conceptualization, S.A.P., A.F., A.B.K., A.A.-A., J.P.W., and P.R.-K.; methodology, S.A.P. and A.F.; validation, S.A.P., A.F., A.B.K., and P.R.-K.; formal analysis, S.A.P., A.F., A.B.K., and J.P.W.; investigation, S.A.P. and A.F.; data curation, K.V.; writing—original draft preparation, S.A.P.; writing—review and editing, S.A.P.; visualization, K.V.; supervision, J.P.W., A.B., and P.R.-K.; project administration, P.R.-K.; funding acquisition, P.R.-K. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the B. Braun Science Foundation and Moessner Science Foundation. The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding programme Open Access Publishing.

**Institutional Review Board Statement:** This clinical trial respected the principles of the Declaration of Helsinki on human experimentation and was conducted in accordance with Good Clinical Practice [53]. Prior to patient recruitment, the study was approved by the local ethics committee of the University of Freiburg (EK No. 255/16) and registered in an international clinical study register (German Clinical Trials Register; DRKS00011137).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets used and/ or analysed during this study are available from the corresponding author on reasonable request.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

#### References

- Kassebaum, N.J.; Bernabé, E.; Dahiya, M.; Bhandari, B.; Murray, C.J.L.; Marcenes, W. Global Burden of Severe Periodontitis in 1990–2010. J. Dent. Res. 2014, 93, 1045–1053. [CrossRef]
- Jepsen, S.; Deschner, J.; Braun, A.; Schwarz, F.; Eberhard, J. Calculus removal and the prevention of its formation. *Periodontol.* 2000 2010, 55, 167–188. [CrossRef]
- 3. Slots, J. Position Paper: Systemic Antibiotics in Periodontics. J. Periodontol. 2004, 75, 1553–1565. [CrossRef]
- 4. Anwar, H.; Strap, J.L.; Costerton, J.W. Establishment of aging biofilms: Possible mechanism of bacterial resistance to antimicrobial therapy. *Antimicrob. Agents Chemother.* **1992**, *36*, 1347–1351. [CrossRef]
- Rams, T.E.; Degener, J.E.; Van Winkelhoff, A.J. Antibiotic Resistance in Human Chronic Periodontitis Microbiota. *J. Periodontol.* 2014, 85, 160–169. [CrossRef] [PubMed]
- 6. Hoffmann, G.; Hartel, M.; Mercer, J.B. Heat for wounds–water-filtered infrared-A (wIRA) for wound healing—A review. *Ger. Med. Sci.* 2016, *14*, Doc08.
- 7. Fuchs, S.M.; Fluhr, J.W.; Bankova, L.; Tittelbach, J.; Hoffmann, G.; Elsner, P. Photodynamic therapy (PDT) and waterfiltered infrared A (wIRA) in patients with recalcitrant common hand and foot warts. *Ger. Med. Sci.* 2004, *2*, Doc08. [PubMed]
- 8. Bühring, M.; Kraft, K.; Matthiessen, P.F.; Resch, K.D.; Stange, R.; Stiller, N.; Uehleke, B. *Hydro- und Thermotherapie. Naturheilverfahren: Und Unkonventionelle Medizinische Richtungen. Grundlagen, Methoden, Nachweissituationen,* 31st ed.; Springer: Berlin/Heidelberg, Germany, 2004.
- Ostberg, J.R.; Repasky, E.A. Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. *Cancer Immunol. Immunother.* 2006, 55, 292–298. [CrossRef] [PubMed]
- 10. Van Bruggen, I.; Robertson, T.; Papadimitriou, J. The effect of mild hyperthermia on the morphology and function of murine resident peritoneal macrophages. *Exp. Mol. Pathol.* **1991**, *55*, 119–134. [CrossRef]
- 11. Yan, X.; Xiu, F.; An, H.; Wang, X.; Wang, J.; Cao, X. Fever range temperature promotes TLR4 expression and signaling in dendritic cells. *Life Sci.* 2007, *80*, 307–313. [CrossRef] [PubMed]
- 12. Berglundh, T.; Donati, M. Aspects of adaptive host response in periodontitis. J. Clin. Periodontol. 2005, 32, 87–107. [CrossRef]
- 13. Kinane, D.F.; Bartold, P.M. Clinical relevance of the host responses of periodontitis. Periodontol. 2000 2007, 43, 278–293. [CrossRef]
- 14. Ohlrich, E.J.; Cullinan, M.P.; Seymour, G.J. The immunopathogenesis of periodontal disease. *Aust. Dent. J.* **2009**, *54*, S2–S10. [CrossRef]
- 15. A Mackowiak, P.; Marling-Cason, M. Hyperthermic enhancement of serum antimicrobial activity: Mechanism by which fever might exert a beneficial effect on the outcome of gram-negative sepsis. *Infect. Immun.* **1983**, *39*, 38–42. [CrossRef]
- Curtis, M.A.; Percival, R.S.; Devine, D.; Darveau, R.P.; Coats, S.R.; Rangarajan, M.; Tarelli, E.; Marsh, P.D. Temperature-Dependent Modulation ofPorphyromonas gingivalisLipid A Structure and Interaction with the Innate Host Defenses. *Infect. Immun.* 2011, 79, 1187–1193. [CrossRef] [PubMed]
- 17. Percival, R.S.; Marsh, P.D.; Devine, D.A.; Rangarajan, M.; Aduse-Opoku, J.; Shepherd, P.; Curtis, M.A. Effect of temperature on growth, hemagglutination, and protease activity of Porphyromonas gingivalis. *Infect. Immun.* **1999**, *67*, 1917–1921. [CrossRef]
- 18. Rattan, S.I.S.; Sejersen, H.; Fernandes, R.A.; Luo, W. Stress-Mediated Hormetic Modulation of Aging, Wound Healing, and Angiogenesis in Human Cells. *Ann. N. Y. Acad. Sci.* **2007**, *1119*, 112–121. [CrossRef] [PubMed]
- 19. Chung, E.; Sampson, A.C.; Rylander, M.N. Influence of Heating and Cyclic Tension on the Induction of Heat Shock Proteins and Bone-Related Proteins by MC3T3-E1 Cells. *BioMed Res. Int.* 2014, 2014, 1–16. [CrossRef]
- 20. Shui, C.; Scutt, A. Mild Heat Shock Induces Proliferation, Alkaline Phosphatase Activity, and Mineralization in Human Bone Marrow Stromal Cells and Mg-63 Cells In Vitro. *J. Bone Miner. Res.* **2001**, *16*, 731–741. [CrossRef]
- Karygianni, L.; Ruf, S.; Follo, M.; Hellwig, E.; Bucher, M.; Anderson, A.C.; Vach, K.; Al-Ahmad, A. Novel Broad-Spectrum Antimicrobial Photoinactivation of In SituOral Biofilms by Visible Light plus Water-Filtered Infrared A. *Appl. Environ. Microbiol.* 2014, 80, 7324–7336. [CrossRef] [PubMed]
- 22. Hartel, M.; Hoffmann, G.; Wente, M.N.; Martignoni, M.E.; Büchler, M.W.; Friess, H. Randomized clinical trial of the influence of local water-filtered infrared A irradiation on wound healing after abdominal surgery. *BJS* **2006**, *93*, 952–960. [CrossRef] [PubMed]
- 23. Künzli, B.M.; Liebl, F.; Nuhn, P.; Schuster, T.; Friess, H.; Hartel, M. Impact of Preoperative Local Water-Filtered Infrared A Irradiation on Postoperative Wound Healing. *Ann. Surg.* **2013**, *258*, 887–894. [CrossRef] [PubMed]
- 24. Hoffmann, G. Principles and working mechanisms of water-filtered infrared-A (wIRA) in relation to wound healing. *GMS Krankenhhyg Interdiszip.* 2007, 2, 54.
- 25. Hartel, M.; Illing, P.; Mercer, J.B.; Lademann, J.; Daeschlein, G.; Hoffmann, G. Therapy of acute wounds with water-filtered infrared-A (wIRA). *GMS Krankenhhyg Interdiszip*. **2007**, *2*, Doc53.
- 26. Dirschka, T.; Radny, P.; Dominicus, R.; Mensing, H.; Brüning, H.; Jenne, L.; Karl, L.; Sebastian, M.; Oster-Schmidt, C.; Klövekorn, W.; et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: Results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. *Br. J. Dermatol.* 2011, 166, 137–146. [CrossRef]

- 27. Von Felbert, V.; Schumann, H.; Mercer, J.B.; Strasser, W.; Daeschlein, G.; Hoffmann, G. Therapy of chronic wounds with water-filtered infrared-A (wIRA). *GMS Krankenhhyg Interdiszip*. **2008**, *2*, Doc52.
- 28. Rad, M.R.; Wise, G.E.; Brooks, H.; Flanagan, M.B.; Yao, S. Activation of proliferation and differentiation of dental follicle stem cells (DFSCs) by heat stress. *Cell Prolif.* **2012**, *46*, 58–66. [CrossRef]
- 29. Mercer, J.B.; Nielsen, S.P.; Hoffmann, G. Improvement of wound healing by water-filtered infrared-A (wIRA) in patients with chronic venous stasis ulcers of the lower legs including evaluation using infrared thermography. *Ger Med Sci* 2008, *6*, 19675738.
- 30. Weerakoon, A.T.; Meyers, I.A.; Symons, A.L.; Walsh, L.J. Pulpal heat changes with newly developed resin photopolymerisa-tion systems. *Aust. Endod. J.* 2002, *28*, 108–111. [CrossRef]
- 31. A Copulos, T.; Low, S.B.; Walker, C.B.; Trebilcock, Y.Y.; Hefti, A.F. Comparative Analysis Between a Modified Ultrasonic Tip and Hand Instruments on Clinical Parameters of Periodontal Disease. *J. Periodontol.* **1993**, *64*, 694–700. [CrossRef]
- 32. Haffajee, A.D.; Cugini, M.A.; Dibart, S.; Smith, C.; Kent, R.L.; Socransky, S.S. The effect of SRP on the clinical and microbiological parameters of periodontal diseases. *J. Clin. Periodontol.* **1997**, *24*, 324–334. [CrossRef]
- 33. Kinane, D.F.; Radvar, M. A six-month comparison of three periodontal local antimicrobial therapies in persistent perio-dontal pockets. *J. Periodontol.* **1999**, *70*, 1–7. [CrossRef] [PubMed]
- Pihlstrom, B.L.; McHuon, R.B.; Oliphant, T.H.; Ortiz-Campos, C. Comparison of surgical and nonsurgical treatment of periodontal disease A review of current studies and additional results after 6 1/2 years. J. Clin. Periodontol. 1983, 10, 524–541. [CrossRef] [PubMed]
- 35. Badersten, A.; Nilveus, R.; Egelberg, J. Effect of nonsurgical periodontal therapy III. Single versus repeated instrumentation. *J. Clin. Periodontol.* **1984**, *11*, 114–124. [CrossRef]
- 36. Badersten, A.; Nilveus, R.; Egelberg, J. Effect of nonsurgical periodontal therapy. I. Moderately advanced periodontitis. *J. Clin. Periodontol.* **1981**, *8*, 57–72. [CrossRef] [PubMed]
- Cugini, M.A.; Haffajee, A.D.; Smith, C.; Kent, R.L.; Socransky, S.S. The effect of scaling and root planing on the clinical and microbiological parameters of periodontal diseases: 12-month results. *J. Clin. Periodontol.* 2000, 27, 30–36. [CrossRef]
- 38. Morrison, E.C.; Ramfjord, S.P.; Hill, R.W. Short-term effects of initial, nonsurgical periodontal treatment (hygienic phase). J. Clin. *Periodontol.* **1980**, *7*, 199–211. [CrossRef]
- 39. Cobb, C.M. Clinical significance of non-surgical periodontal therapy: An evidence-based perspective of scaling and root planing. *J. Clin. Periodontol.* **2002**, *29*, 22–32. [CrossRef]
- Reddy, M.S.; Aichelmann-Reidy, M.E.; Avila-Ortiz, G.; Klokkevold, P.R.; Murphy, K.G.; Rosen, P.S.; Schallhorn, R.G.; Sculean, A.; Wang, H.-L. Periodontal Regeneration – Furcation Defects: A Consensus Report From the AAP Regeneration Workshop. J. Periodontol. 2015, 86, S131–S133. [CrossRef]
- Kruse, A.B.; Akakpo, D.L.; Maamar, R.; Woelber, J.P.; Al-Ahmad, A.; Vach, K.; Ratka-Krueger, P. Trehalose powder for subgingival air-polishing during periodontal maintenance therapy: A randomized controlled trial. *J. Periodontol.* 2018, 90, 263–270. [CrossRef] [PubMed]
- 42. Al-Ahmad, A.; Tennert, C.; Karygianni, L.; Wrbas, K.T.; Hellwig, E.; Altenburger, M.J. Antimicrobial photodynamic therapy using visible light plus water-filtered infrared-A (wIRA). *J. Med Microbiol.* **2013**, *62*, 467–473. [CrossRef]
- 43. Mongardini, C.; Di Tanna, G.L.; Pilloni, A. Light-activated disinfection using a light-emitting diode lamp in the red spec-trum: Clinical and microbiological short-term findings on periodontitis patients in maintenance. A randomized controlled split-mouth clinical trial. *Lasers Med. Sci.* 2014, *29*, 1–8. [CrossRef] [PubMed]
- 44. Arweiler, N.B.; Pietruska, M.; Pietruski, J.; Skurska, A.; Dolińska, E.; Heumann, C.; Auschill, T.M.; Sculean, A. Six-month results following treatment of aggressive periodontitis with antimicrobial photodynamic therapy or amoxicillin and metronidazole. *Clin. Oral Investig.* **2014**, *18*, 2129–2135. [CrossRef] [PubMed]
- 45. De Oliveira, R.R.; Schwartz-Filho, H.O.; Novaes, A.B.; Taba, M. Antimicrobial photodynamic therapy in the non-surgical treatment of aggressive periodontitis: A preliminary randomized controlled clinical study. *J. Periodontol.* **2007**, *78*, 965–973. [CrossRef] [PubMed]
- 46. Goodrich, J.K.; Di Rienzi, S.C.; Poole, A.C.; Koren, O.; Walters, W.A.; Caporaso, J.G.; Knight, R.; Ley, R.E. Conducting a Microbiome Study. *Cell* **2014**, *158*, 250–262. [CrossRef] [PubMed]
- 47. Lampert, T.; Von Der Lippe, E.; Muters, S. Verbreitung des Rauchens in der Erwachsenenbevölkerung in Deutschland. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2013, 56, 802–808. [CrossRef] [PubMed]
- 48. Ainamo, J.; Barmes, D.; Beagrie, G.; Cutress, T.; Martin, J.; Sardo-Infirri, J. Development of the World Health Organization (WHO) community periodontal index of treatment needs (CPITN). *Int. Dent. J.* **1982**, *32*, 281–291.
- 49. O'>Leary, T.J.; Drake, R.B.; Naylor, J.E. The Plaque Control Record. J. Periodontol. 1972, 43, 38. [CrossRef]
- 50. Saxer, U.P.; Mühlemann, H.R. Motivation und Aufklärung [Motivation and education]. SSO Schweiz Monatsschr Zahnheilkd. 1975, 85, 905–919.
- 51. Grossi, S.G.; Dunford, R.G.; Ho, A.; Koch, G.; Machtei, E.E.; Genco, R.J. Sources of error for periodontal probing measurements. *J. Periodontal Res.* **1996**, *31*, 330–336. [CrossRef]
- 52. Braun, A.; Jepsen, S.; Deimling, D.; Ratka-Krüger, P. Subjective intensity of pain during supportive periodontal treatment using a sonic scaler or an Er:YAG laser. *J. Clin. Periodontol.* **2010**, *37*, 340–345. [CrossRef] [PubMed]
- 53. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. *JAMA* 2013, *310*, 2191–2194. [CrossRef] [PubMed]